InvestWiser

Faron Pharmaceuticals Oy

FARONNasdaq HelsinkiHealthcareMarket value 64 m EUR
0.32EUR +0.5%
last day · Price as of 20 November 2026

The answer first

Does Faron Pharmaceuticals beat the market?

No, Faron Pharmaceuticals has not beaten the market over the last year.

Faron Pharmaceuticals−85.6%Helsinki (OMXHGI)+16.0%

Max for seven days

Follow Faron Pharmaceuticals with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 20 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Faron Pharmaceuticals

From today, at a price of 0.32 EUR. Write why you follow Faron Pharmaceuticals, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Faron Pharmaceuticals

Your first answer is free, no account needed.

Do you own Faron Pharmaceuticals, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Faron Pharmaceuticals and a few more. Free, no card.

Past year against the exchange and Super Stock
Faron Pharmaceuticals−85.6%Helsinki (OMXHGI)+16.0%Super Stock+46.4%
18 November 202520 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Faron Pharmaceuticals has fallen 85.6% over the past year, including dividends.
  • The largest fall over the past three years was 92.4%. The price is 94.9% below its peak now.

Who owns Faron Pharmaceuticals? See the major shareholders and their stakes

What do analysts think of Faron Pharmaceuticals?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

Quality–
The company · Fundamentals: the accounts
  • Debt to equityBorrowings divided by equity0.81
  • Asset turnoverSales divided by everything the company owns0.00
  • Return on equityProfit divided by equity–
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value1
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 188 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity5.3
  • P/SPrice divided by sales–
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flow–

The ranking is built on P/E, P/B and P/S.

Trend5
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 174 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−33.6%
  • 6 months−40.2%
  • 9 months−42.9%
  • 12 months−85.6%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−21.4%
3 years, per year
−53.4%
5 years, per year
−40.0%
Year to date
−84.9%
Largest fall, 3 years
−92.4%
From a peak to the bottom
From the peak now
−94.9%
How far the price is from the peak
Volatility, 1 year
83.7%
How much the price swings over a year
Beta, 1 year
0.76
How much the price moves when the market moves

Return with dividends reinvested.

About Faron Pharmaceuticals

Faron Pharmaceuticals Oy is a company in healthcare, listed on Nasdaq Helsinki. By market value, Faron Pharmaceuticals is number 9 of 16 companies in healthcare on Nasdaq Helsinki. Faron Pharmaceuticals has not paid a dividend in the past twelve months. The next report from Faron Pharmaceuticals is expected on 4 March 2027. The share trades in EUR. It has around 36 employees.

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. It is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combination with care therapies, azacitidine, and other hypomethylating agents in relapsed/refractory myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

See the full analysis of Faron Pharmaceuticals.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Helsinki

Explore the stock market